FRBNY Letter from John J Ruocco from Board of Directorrs Re annual report for Citigroup Inc as of December 31 2007

Attached to this letter is an examiner summar

Physical properties and radius variations in the HAT-P-5 planetary system from simultaneous four-colour photometry

The radii of giant planets, as measured from transit observations, may vary with wavelength due to Rayleigh scattering or variations in opacity. Such an effect is predicted to be large enough to detect using ground-based observations at multiple wavelengths. We present defocussed photometry of a transit in the HAT-P-5 system, obtained simultaneously through Stromgren u, Gunn g and r, and Johnson I filters. Two more transit events were observed through a Gunn r filter. We detect a substantially larger planetary radius in u, but the effect is greater than predicted using theoretical model atmospheres of gaseous planets. This phenomenon is most likely to be due to systematic errors present in the u-band photometry, stemming from variations in the transparency of Earth's atmosphere at these short wavelengths. We use our data to calculate an improved orbital ephemeris and to refine the measured physical properties of the system. The planet HAT-P-5b has a mass of 1.06 +/- 0.11 +/- 0.01 Mjup and a radius of 1.252 +/- 0.042 +/- 0.008 Rjup (statistical and systematic errors respectively), making it slightly larger than expected according to standard models of coreless gas-giant planets. Its equilibrium temperature of 1517 +/- 29 K is within 60K of that of the extensively-studied planet HD 209458b.Comment: Version 2 corrects the accidental omission of one author in the arXiv metadata. Accepted for publication in MNRAS. 9 pages, 4 figures, 7 tables. The properties of HAT-P-5 have been added to the Transiting Extrasolar Planet Catalogue at http://www.astro.keele.ac.uk/~jkt/tepcat

OCC and FRBNY Letter from John C Lyons and John Ruocco to David Bushnell Re Operational Risk Management

This letter is addressed to David Bushnel

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

Background Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (RIVaroxaban Evaluation in Real life setting) is an ongoing international, prospective registry of patients with newly diagnosed non-valvular atrial fibrillation (NVAF) and at least one investigator-determined risk factor for stroke who received rivaroxaban as an initial treatment for the prevention of thromboembolic stroke. The aim of this paper is to describe the design of the RIVER registry and baseline characteristics of patients with newly diagnosed NVAF who received rivaroxaban as an initial treatment. Methods and results Between January 2014 and June 2017, RIVER investigators recruited 5072 patients at 309 centres in 17 countries. The aim was to enroll consecutive patients at sites where rivaroxaban was already routinely prescribed for stroke prevention. Each patient is being followed up prospectively for a minimum of 2-years. The registry will capture data on the rate and nature of all thromboembolic events (stroke / systemic embolism), bleeding complications, all-cause mortality and other major cardiovascular events as they occur. Data quality is assured through a combination of remote electronic monitoring and onsite monitoring (including source data verification in 10% of cases). Patients were mostly enrolled by cardiologists (n = 3776, 74.6%), by internal medicine specialists 14.2% (n = 718) and by primary care/general practice physicians 8.2% (n = 417). The mean (SD) age of the population was 69.5 (11.0) years, 44.3% were women. Mean (SD) CHADS2 score was 1.9 (1.2) and CHA2DS2-VASc scores was 3.2 (1.6). Almost all patients (98.5%) were prescribed with once daily dose of rivaroxaban, most commonly 20 mg (76.5%) and 15 mg (20.0%) as their initial treatment; 17.9% of patients received concomitant antiplatelet therapy. Most patients enrolled in RIVER met the recommended threshold for AC therapy (86.6% for 2012 ESC Guidelines, and 79.8% of patients according to 2016 ESC Guidelines). Conclusions The RIVER prospective registry will expand our knowledge of how rivaroxaban is prescribed in everyday practice and whether evidence from clinical trials can be translated to the broader cross-section of patients in the real world

The Top 10 oomycete pathogens in molecular plant pathology

Oomycetes form a deep lineage of eukaryotic organisms that includes a large number of plant pathogens which threaten natural and managed ecosystems. We undertook a survey to query the community for their ranking of plant-pathogenic oomycete species based on scientific and economic importance. In total, we received 263 votes from 62 scientists in 15 countries for a total of 33 species. The Top 10 species and their ranking are: (1) Phytophthora infestans; (2, tied) Hyaloperonospora arabidopsidis; (2, tied) Phytophthora ramorum; (4) Phytophthora sojae; (5) Phytophthora capsici; (6) Plasmopara viticola; (7) Phytophthora cinnamomi; (8, tied) Phytophthora parasitica; (8, tied) Pythium ultimum; and (10) Albugo candida. This article provides an introduction to these 10 taxa and a snapshot of current research. We hope that the list will serve as a benchmark for future trends in oomycete research.Keywords: microbiology, diversity, genomics, oomycetes plant patholog